Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0151744 (myocardial ischemia)
 31,282 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

We studied the long-term outcome of 87 adults with acute leukemia (age 15-59 years at transplant, median 27; 44 myeloid, 42 lymphoblastic, one biphenotypic) who were alive in continuous remission 2 years after a marrow (n = 74) or blood stem cell (n = 13) autograft. Nine relapsed 25-50 months (median 38) after transplantation. Five relapses were straightforward with no karyotypic or morphologic evolution of the original disease. Four recurrences were unusual, with development of myelodysplasia (n = 3) or myeloproliferative disease (n = 1). Five patients died of relapsed disease and four are still alive. Two patients died of complications related to the transplant, and one of ischemic heart disease. Seventy-nine patients (91%) are alive in remission 24-149 months (median 67) after transplantation (75 in continuous remission and four after further therapy) with Karnofsky scores of 80-100% (median 100%). The 8-year probabilities of survival, toxic death, and relapse (from the 2-year mark) are 89%, 3% and 12%. Eleven (12%) survivors had creatinine levels of >110 micromol/l (one more than double), and 14 (16%) had bilirubin levels of >17 mmol/l (one more than double) at the last follow-up. None of the following factors was found to be predictive for survival, non-relapse death, or relapse from the 2-year mark in multivariate analysis: age, sex, type of leukemia, disease stage, diagnosis, conditioning, origin of cells, and nucleated cell dose. We conclude that adult patients with acute leukemia who are alive and well 2 years following an autograft have a high probability of being cured, and the incidence of long-term liver and kidney dysfunction measured by serum bilirubin and creatinine is low.
 ...
PMID:Long-term outcome of adult acute leukemia patients who are alive and well 2 years after autologous blood or marrow transplantation. 1033 41

The results of the survey 16 children with acute lymphoblastic leukemia, in which the resulting protocol chemotherapy using doxorubicin developed toxic anthracycline-induced cardiomyopathy. The control group was 20 healthy children of similar age studied. Distribution of research groups included age status and cumulative dose of doxorubicin. Studies of the cardiovascular system in children with acute leukemia was conducted before and at the end of each protocol chemotherapy. It is noted that the complaints of the cardiovascular system as palpitations and disruptions in the heart, cardialgia, autonomic crises occurred at the end of the first phase I protocol chemotherapy. Severity of complaints prevalent in patients with higher cumulative dose of doxorubicin. Noted a decrease in left ventricular contractile capacity and the development of myocardial ischemia in patients with acute leukemia at the end of the first phase II protocol. The increase pro-brain natriuretic peptide in all patients with acute lymphoblastic leukemia at the end of the first phase I protocols that can be considered as an early diagnostic marker of myocardial injury in these patients.
 ...
PMID:[Diagnostic markers of anthracycline-induced cardiomyopathy in children with acute leukemia]. 2528 93